ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall survival (OS) results of the Phase III MONALEESA-3 trial - YouTube
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Asco 2019 – Novartis looks to premenopausal survival to reinvigorate Kisqali | Evaluate
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | NEJM
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 | Journal of Clinical Oncology
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..." - YouTube
KISQALI® (ribociclib) Treatment: 1L HR+/HER2- mBC | HCP
Kaplan–Meier analysis of locally assessed progression-free survival in... | Download Scientific Diagram
![ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).](https://larvolclin.s3.us-west-2.amazonaws.com/resize_162308040295527161060be3dd24570a.png "ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).")
ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting - The ASCO Post
ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
MONALEESA-3 OS Update - Slideset Download - Clinical Oncology 2021 | CCO
Efficacy of KISQALI® (ribociclib) + Fulvestrant in 1L Postmenopausal | HCP
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
